JACC. Advances · 2026
Antibiotic Prophylaxis for Congenital Cardiac Catheterizations: Lessons Learned From the Pediatric Health Information System.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Issa Bayan, Shibbani Kamel, Zaniletti Isabella, Hall Matt, Justino Henri, El-Said Howaida, Gordon Brent M
Аннотация
BACKGROUND: There is significant antibiotic prophylaxis (ABP) variability before congenital cardiac catheterization procedures. The true incidence of procedure-related infective endocarditis (IE) remains unclear.
OBJECTIVE: This study aimed to evaluate national periprocedural ABP utilization patterns and determine whether ABP dosing strategies are associated with early postprocedural IE.
METHODS: A retrospective cohort study was conducted using data from the Pediatric Health Information System from 39 pediatric centers. Data were collected on the following procedures: patent ductus arteriosus (PDA) device occlusion, atrial septal defect device occlusion, ventricular septal defect device occlusion, transcatheter pulmonary valve replacement (TPVR), and pulmonary or aortic balloon valvuloplasty. Outcomes assessed were: 1) rate and pattern of periprocedural antibiotic use and 2) incidence of early IE within 30-days postprocedure.
RESULTS: A total of 20,580 procedures were analyzed. Antibiotic dosing varied significantly by procedure, with the proportion of patients receiving ≥2 doses ranging from 38.8% for PDA closure to 85.7% for TPVR. A total of 15 IE cases (0.07%) were identified within 30 days, more than half of which followed TPVR (53%). The incidence of early IE varied significantly by procedure type (P = 0.003): TPVR (0.27%), pulmonary valvuloplasty (0.12%), atrial septal defect closure (0.04%), and PDA closure (0.02%). There was no measurable association between ABP and early IE.
CONCLUSIONS: Procedure-related IE is exceedingly rare and is significantly related to procedure type. We did not observe a measurable association between early IE and ABP dosing. These findings underscore the need for standardized, evidence-based guidelines to optimize antibiotic protocols for congenital cardiac catheterization.
OBJECTIVE: This study aimed to evaluate national periprocedural ABP utilization patterns and determine whether ABP dosing strategies are associated with early postprocedural IE.
METHODS: A retrospective cohort study was conducted using data from the Pediatric Health Information System from 39 pediatric centers. Data were collected on the following procedures: patent ductus arteriosus (PDA) device occlusion, atrial septal defect device occlusion, ventricular septal defect device occlusion, transcatheter pulmonary valve replacement (TPVR), and pulmonary or aortic balloon valvuloplasty. Outcomes assessed were: 1) rate and pattern of periprocedural antibiotic use and 2) incidence of early IE within 30-days postprocedure.
RESULTS: A total of 20,580 procedures were analyzed. Antibiotic dosing varied significantly by procedure, with the proportion of patients receiving ≥2 doses ranging from 38.8% for PDA closure to 85.7% for TPVR. A total of 15 IE cases (0.07%) were identified within 30 days, more than half of which followed TPVR (53%). The incidence of early IE varied significantly by procedure type (P = 0.003): TPVR (0.27%), pulmonary valvuloplasty (0.12%), atrial septal defect closure (0.04%), and PDA closure (0.02%). There was no measurable association between ABP and early IE.
CONCLUSIONS: Procedure-related IE is exceedingly rare and is significantly related to procedure type. We did not observe a measurable association between early IE and ABP dosing. These findings underscore the need for standardized, evidence-based guidelines to optimize antibiotic protocols for congenital cardiac catheterization.